トクシマケン イシカイ トウニョウビョウ タイサクハン ダイ1ジ ダイ2ジ カツドウ ノ セイカ

Objective : The effectiveness of diabetes prevention programs for the general population in Tokushima Prefecture was investigated. The programs were designed by Tokushima Medical Association’ s（TMA’s）Steering Committee for Diabetes Prevention. Research design and methods : The committee promoted diabetes prevention by disseminating educational messages on diabetes to the general public and medical care providers, and establishing a referral system among public health centers and medical institutes throughout Tokushima Prefecture during the period from ２００４ to ２００９. The outcome of these activities were evaluated by analyzing data from the Prefectural Health and Nutrition Survey in Tokushima conducted in１９９７（n＝ ９９８）,２００３ （n＝１００８） and ２０１０ （n＝１１３０）, and then comparing these results with those of the national survey at the corresponding times. Results : The percentage of subjects with glucose intolerance at the time of initiation of the prevention program in Tokushima tended to increase from １９９７ to ２００３, but was slightly decreased in ２０１０, although the differences were not statistically significant. However, the percentage of subjects with glucose intolerance was significantly increased throughout Japan during the same period. Obesity parameters, physical activity evaluated by the number of steps and the average total energy intake changed favorably in parallel with changes in the prevalence of diabetes during the study period in Tokushima. Conclusion : The diabetes prevention programs initiated by the TMA’s committee may be useful in ameliorating the situation of diabetes in Tokushima Prefecture

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Biochemical Systematics of Three Species of the Japanese Long-Tailed Field Mice; Apodemus speciosus, A. giliacus and A. argenteus : Taxnomy and Systematics

Volume: 6Start Page: 1005End Page: 101

Irradiation effect on magnetic properties of FeRh thin films with energetic C60 cluster ion beam

Effect of energetic C60 cluster ion irradiation on magnetic properties in FeRh thin films was examined by SQUID and XMCD measurements. The XMCD signal for the C60 irradiated samples is larger than that for the C1 samples in the initial stage of the irradiation. In contrast, as for the irradiation with larger ion fluence, the XMCD spectrum for the sample irradiated with C1 ion is larger than that for the sample irradiated with C60 cluster ion. Although the magnetization for the C60 irradiation samples continuously decreases with increasing in the ion fluence, the saturation magnetization for the C1 irradiation samples increases with increasing in the ion fluence. Considering these different behaviors in the irradiation induced ferromagnetism, the cluster ion can effectively deposit the apparent elastic collision energy at the surface region in the film, which effectively causes the ferromagnetic state at the surface of the films

Reduction in Crystal Size of Flexible Porous Coordination Polymers Built from Luminescent Ru(II)-Metalloligands

In this study, we examined the reduction in crystal size of the porous coordination polymers (PCPs) {Sr₄(H₂O)₉]<b>­[4Ru]</b>₂­·9H₂O]} (<b>Sr</b>_<b>2</b><b>[4Ru]</b>) and [Mg­(H₂O)₆]­{[Mg₂(H₂O)₃<b>­[4Ru]</b>­·4H₂O} (<b>Mg</b>_<b>2</b><b>[4Ru]</b>) composed of a luminescent metalloligand [Ru­(4,4′-dcbpy)]^4–­(<b>[4Ru]</b>; 4,4′-dcbpy = 4,4′-dicarboxy-2,2′-bipyridine) using a coordination modulation method. Scanning electron microscopy measurements clearly show that the sizes of crystals of <b>Sr</b>_<b>2</b><b>[4Ru]</b> and <b>Mg</b>_<b>2</b><b>[4Ru]</b> were successfully reduced to the mesoscale (about 500 nm width and 10 nm thickness for <b>Sr</b>_<b>2</b><b>[4Ru]</b> (abbreviated as <i>m</i>-<b>Sr</b>_<b>2</b><b>[4Ru]</b>) and about 1 μm width and 30 nm thickness for <b>Mg</b>_<b>2</b><b>[4Ru]</b> (abbreviated as <i>m</i>-<b>Mg</b>_<b>2</b><b>[4Ru]</b>)) using lauric acid as a coordination modulator. Interestingly, the nanocrystals of <i>m</i>-<b>Sr</b>_<b>2</b><b>[4Ru]</b> formed flower-like aggregates with diameters of 1 μm, whereas flower-like aggregates were not formed in <i>m</i>-<b>Mg</b>_<b>2</b><b>[4Ru]</b>. Water vapor adsorption isotherms of these nanocrystals suggest that the water adsorption behavior of <i>m</i>-<b>Sr</b>_<b>2</b><b>[4Ru]</b>, which has a three-dimensional lattice structure containing small pores, is significantly different from that of the bulk <b>Sr</b>_<b>2</b><b>[4Ru]</b> crystal, as shown by the vapor adsorption isotherm. In contrast, <i>m</i>-<b>Mg</b>_<b>2</b><b>[4Ru]</b>, which has a two-dimensional sheet structure, had an adsorption isotherm very similar to that of the bulk sample. These contrasting results suggest that the dimensionality of the coordination framework is an important factor for the guest adsorption behavior of nanocrystalline PCPs

Enterogenous cyst of pediatric testis: a case report

Abstract Background An enterogenous cyst is a rare entity categorized as an intestinal cyst. In most cases, enterogenous cysts are seen in the mediastinum, peritoneal cavity, spinal canal, subarachnoid space, and cerebral ventricle. Case presentation A 14-year-old Asian (Japanese) boy reported feeling pain in his left groin, and a mass was found. We did not perform orchiectomy because intraoperative frozen sections showed no malignant findings. On histological examination the resected specimens contained columnar epithelium surrounded by smooth muscle. Based on these findings, an enterogenous cyst was diagnosed. Few cases of enterogenous cysts of the testis have been described. Conclusion We encountered a case of an enterogenous cyst of a pediatric testis